NEW YORK, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the fiscal year ended September 30, 2016 after the market close on Thursday, December 22, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.
|Conference Call & Webcast|
|Thursday, December 22 at 5:00pm Eastern Time|
|Replays – Available through December 29, 2016|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being evaluated in combination with anti-VEGF injections in a Phase 3 clinical program for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information about the company may be found at www.ohrpharmaceutical.com.
Source:Ohr Pharmaceutical, Inc.